Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

Darja Karpova, PhD, Susanne Brauninger, MD, Eliza Wiercinska, PhD, Ariane Kraemer, B.Sc., Belinda Stock, Jochen Graff, MD, Christophe Escot, Garry Douglas, PhD, Barbara Romagnoli, PhD, Eric Chevalier, PhD, Klaus Dembowsky, MD PhD, Leon Hooftman, MD, Halvard Bonig, MD MA

Blood (2015) 126 (23): 511.

https://doi.org/10.1182/blood.V126.23.511.511

Published: 2015

Journal Articles

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD, Pierre Zachee, MD, PhD, Norbert Vey, Dimitri Breems, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD, Phillip Debnam, PhD, Lindsey Needham, PhD, Lindsay Bawden, PhD, Leon Hooftman, MD

Blood (2010) 116 (21): 3279.

https://doi.org/10.1182/blood.V116.21.3279.3279

Published: 2010

Journal Articles

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Emma M Smith, PhD, Brian A Walker, PhD, Emma L Davenport, PhD, Lauren I Aronson, BSc.Hons., David Krige, PhD, Leon Hooftman, MD, Alan Drummond, PhD, Gareth J Morgan, MD, PhD, Faith Davies, MD

Blood (2009) 114 (22): 607.

https://doi.org/10.1182/blood.V114.22.607.607

Published: 2009

Journal Articles

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

Faith E. Davies, MD, Hannah E. Moore, Emma L. Davenport, PhD, Alan S. Dunlop, Srikanth Muralikrishnan, David Krige, PhD, Leon Hooftman, MD, Gareth Morgan, PhD

Blood (2007) 110 (11): 2505.

https://doi.org/10.1182/blood.V110.11.2505.2505

Published: 2007

Journal Articles

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Faith Davies, MD, Gert Ossenkoppele, MD, Pierre Zachee, MD, Richard Noppeney, MD, Alan Burnett, MD, Michel Delforge, MD, Pieter Sonneveld, MD, Gareth Morgan, MD, Sonja Zweegman, MD, Dimitri Breems, MD, Alison Richardson, PhD, Leon Hooftman, MD, Bob Lowenberg, MD

Blood (2007) 110 (11): 443.

https://doi.org/10.1182/blood.V110.11.443.443

Published: 2007

NARROW

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only